FenBen in Stage 4 cancer

Summary

This video explores the potential of fenbendazol, a veterinary antiparasitic drug, as an anti-cancer agent through a detailed review of three case studies involving advanced cancers—breast, prostate, and melanoma. Each patient, initially facing terminal diagnoses, experienced remarkable tumor regression and sustained remission after self-administering fenbendazol, with no reported adverse effects. The speaker emphasizes that these cases are preliminary and not medical advice, highlighting the lack of large-scale trials due to the drug being off-patent. Historical parallels, like James Lind’s scurvy study, illustrate how small observations can lead to major breakthroughs, advocating further research into fenbendazol’s potential in oncology.

Takeaways

• 😀 Fenbendazole, a veterinary drug, has shown potential as an anti-cancer agent in a few small case studies, though it is not officially approved for human use.
• 😀 Fenbendazole is inexpensive, widely available, and generic, making it an accessible option compared to more expensive cancer treatments.
• 😀 The first case involved an 83-year-old woman with stage 4 metastatic breast cancer who went into complete remission after using fenbendazole for 8 months alongside other treatments.
• 😀 In the first case, PET scans showed no abnormal metabolic activity after 8 months of fenbendazole use, indicating potential tumor regression.
• 😀 The second case, involving a 75-year-old man with metastatic prostate cancer, showed sustained regression of his cancer after taking fenbendazole, with undetectable PSA levels after 26 months.
• 😀 A 63-year-old man with melanoma in multiple organs showed no recurrence after 11 months of using fenbendazole, remaining in remission with no reported side effects.
• 😀 The Joe Tippens Protocol, which involves taking fenbendazole three days a week and taking breaks, is commonly followed by people using the drug for cancer treatment.
• 😀 Fenbendazole is often taken with food, ideally fatty food, for better absorption, as suggested in the Joe Tippens Protocol.
• 😀 Despite positive anecdotal reports, the speaker points out that the lack of large-scale randomized clinical trials on fenbendazole for cancer treatment is a major issue in verifying its effectiveness.
• 😀 The speaker compares the lack of research on fenbendazole to historical cases like James Lind's discovery of the cure for scurvy, suggesting that sometimes small observations can lead to major breakthroughs in medicine.
• 😀 The speaker calls for more clinical research into fenbendazole as a potential cancer treatment, arguing that patients with terminal conditions should have the freedom to explore all treatment options, including alternative therapies.

Q & A

What is Fenbendazole, and why is it being discussed as a potential anti-cancer agent?

Fenbendazole is a veterinary medication primarily used as an antiparasitic drug, commonly known as a dog dewormer. It has been proposed as a potential anti-cancer agent because of its reported effects on cancer cell activity, despite not being licensed for human use in the UK.

Why is Fenbendazole considered an inexpensive treatment?

Fenbendazole is considered inexpensive because its patent expired in the early 1990s, making it a generic drug. As a result, various pharmaceutical companies can produce it cheaply, especially in countries like India, where large quantities can be manufactured at low costs.

What is the significance of the first case of the 83-year-old woman with stage 4 breast cancer?

The first case is significant because the 83-year-old woman, diagnosed with metastatic breast cancer, experienced a dramatic turnaround in her condition after self-administering Fenbendazole. Despite being under hospice care and given little hope, the patient went into complete remission after using Fenbendazole alongside conventional treatments.

How did Fenbendazole affect the 83-year-old patient's cancer markers?

Fenbendazole treatment led to a significant drop in the patient's tumor marker (CA2729), from 316 in November 2021 to 36.6 in July 2022, indicating a drastic reduction in tumor size and activity. PET scans also confirmed the absence of abnormal metabolic activity typically associated with cancer.

Was there any adverse effect from the Fenbendazole treatment in the first case?

No adverse effects were reported from the Fenbendazole treatment. The patient continued the daily dose of 220 milligrams for eight months with no side effects, and remains recurrence-free nearly three years after being declared in remission.

What is the Joe Tippens Protocol, and how does it relate to Fenbendazole?

The Joe Tippens Protocol is an alternative cancer treatment regimen that includes Fenbendazole as a core component. It typically involves taking 220 milligrams of Fenbendazole three days a week, alternating with four days off. The protocol also includes the use of CBD oil and curcumin, though it is not an officially prescribed treatment and is not medically endorsed.

How does Fenbendazole differ from conventional cancer treatments?

Fenbendazole is not a conventional cancer treatment. It is an antiparasitic drug originally used in veterinary medicine, unlike typical cancer treatments such as chemotherapy or radiation, which target cancer cells more directly. Fenbendazole's use in cancer is experimental and based on anecdotal reports rather than clinical trials.

What role did vitamin D supplementation play in the 83-year-old woman's treatment?

The woman continued to take vitamin D supplements (5000 IU daily) throughout her Fenbendazole treatment. Vitamin D is believed to play a role in immune function, which might have been beneficial in supporting her overall health and possibly contributing to her cancer remission.

Why are there no large-scale randomized controlled trials (RCTs) for Fenbendazole despite these promising cases?

The lack of large-scale randomized controlled trials for Fenbendazole may be due to financial reasons. Since Fenbendazole is a generic drug with no patent, pharmaceutical companies cannot profit significantly from its production, unlike newer, patented cancer drugs. This financial limitation has likely hindered large-scale research.

What historical medical case does the speaker reference to illustrate the importance of single observations in medical breakthroughs?

The speaker references James Lind, a Scottish naval surgeon who, in 1747, observed that sailors with scurvy improved dramatically when given citrus fruits. This case, despite being based on a small sample, laid the groundwork for the discovery that vitamin C prevents scurvy and led to the adoption of citrus juice in the British Navy.